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Abstract  
 
Background: Genetic variants in the mother and/or infant have been described with evidence to be associated with 
mother-to-child transmission of HIV, but somehow with contradictory results depending on ethnic or geographic 
populations. We aimed at looking at the association between the allelic frequency of some genes with vertical 
transmission or acquisition of HIV in Cameroon. 
Methodology: A total of 262 mothers (212 HIV-infected and 50 HIV non-infected) with their babies (270 in total, 42 
HIV exposed-infected, 178 HIV exposed non-infected and 50 HIV non-exposed) were recruited in Yaounde-
Cameroon. Their genotypes for CCR5-Delta32, CCR5 promoter59029A/G, CCR2-64I, SDF1-3’A andTRIM5α-136Q 
were analyzed using polymerase chain reaction and restriction fragment length polymorphisms.  
Results: Allelic frequencies were 14.7%, 41.9%, 9.5% and 14.7% for CCR2-64I, CCR5-59029-A/G, TRIM5α-136Q, 
SDF1-3’A respectively in the mothers and 18.8%, 35.9%, 11.3% and 20.5% in the babies. No delta 32 mutation in the 
CCR5 gene was found. The mutant genotype was most significantly frequent in the non-transmitter than in the 
transmitter (p= 0.005) for the SDF-1 3'A. SDF1-3’A [Odd ratio = 1.69; 95% confidence interval: 0.1158 to 0.7277); 
was associated to MTCT, P = 0.008.The homozygote mutants for the CCR5-59029-G were significantly higher in the 
infected than in the exposed uninfected babies (p=0.04). The mutations in the other genes were neither implicated in the 
acquisition nor in the transmission.    
Conclusion: SDF1-3’A was associated to the reduction of MTCT. The CCR5-59029-A/G favored acquisition of HIV 
by babies.  Our study showed that polymorphisms in chemokine ligand may be involved in MTCT. 
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Introduction 
 
         After the discovery of the African HIV-protected sex workers (Fowke et al., 1996), followed by the “Berlin 
patient” who was functionally cured of HIV-1-infection by receiving a hematopoietic stem cell transplant from a donor 
with a defective HIV CCR5 co-receptor (Hütter et al., 2009) the possibility of ‘natural’ protective immunity to HIV was 
raised. Indeed, despite 9 months in an intra-uterine environment with HIV, prolonged exposure to virus-containing 
blood and secretions during labor and delivery and ingestion  of breast milk over many months which contain virus-free 
cells, babies born to HIV-infected mothers may remain non-infected. Many factors have been studied and proposed to 
explain these observations. These factors include maternal viral load and immune status, timing and route of delivery, 
viral subtype, and host genetics. Genetic variants in the mother and/or infant have been described with evidence to be 
associated with susceptibility or protection to HIV MTCT by many authors. 
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           The HIV-1 virus entry and infectivity of a cell need the CD4 receptor and at least one co-receptor from multi-CC 
and CXC chemokine receptors (Cicala et al., 2011). Polymorphisms in these CC and CXC chemokine receptors and 
ligand have been found to modulate the infection by HIV.  Among these receptors we can list the 32 bp deletion in the 
coding region of the CCR5 receptor (CCR5-Δ32, rs333). Homozygous for this mutation resists against R5 strains 
infection and the heterozygous genotype gives limited resistance and/or delays the progression to AIDS (Ometto et al., 
2000 ; de Silva and Stumpf, 2004) . The CCR5-59029-A/G (rs1799987) in the promoter region of the CCR5 gene, lead 
to higher expression of this gene. Children with the CCR5-59029-A allele, are less likely to be infected (Singh et al., 
2008). The CCR2-64I polymorphism (rs1799864) has been well-documented in the HIV infection. Individual 
homozygote or heterozygote for 64I mutant have a delay in the progression to AIDS after infection (Berger et al.1999). 
Then the SDF-1-3′A polymorphism (Rs1801157) at the 3′ untranslated region of the SDF-1 gene, which codes for the 
CXCR4 receptor’ ligand, was associated with delayed progression to AIDS in homozygous mutant individuals and 
perinatal transmission of HIV-1 in heterozygous pregnant women (John et al., 2000 ; Ma et al., 2005 ; Alagarasu et al., 
2009) . Lastly a single amino acid substitution (R136Q) in the human Trim5α can confer the ability to restrict HIV-1 
(Javanbakht et al., 2006). 
CCR5 Δ32 heterozygosity exerts a protective effect against perinatal transmission in a Jordanian population 
(Ometto et al., 2000). In a cohort of Kenyan HIV-1-infected, anti-retroviral therapy (ART)-naïve pregnant women and 
their infants, the maternal CCR5 promoter polymorphisms at positions 59029, 59353, 59356, and 59402 were not 
associated with MTCT (John et al., 2001). Katz et al. (2010) found no association between maternal genetic 
polymorphisms in CCR5 and mother-to-child HIV-1 transmission in a Kenyan population (Katz et al., 2010). The same 
findings were reported by singh et al. (2008) from three African cohorts. There was an increased risk of MTCT among 
Kenyan children born to women heterozygous for the SDF-1 3′A polymorphism (John et al., 2000). The CCR2-64I 
allele was associated with protection against early HIV-1 transmission in Argentinian population (Mangano et al., 
2000). This same allele increases the transmission in Kenyan, South African, Ugandan and Malawian population or has 
no impact in the MTCT (Teglas et al., 1999; Brouwer et al., 2005). It was found that polymorphism in 
human TRIM5 may influence susceptibility to HIV-1 infection (Javanbakht et al., 2006) and many more studies later on 
have demonstrated the impact of TRIM5 SNP in HIV infection from an Amsterdam cohort (van Manen et al., 2008; 
Price et al., 2009). A recent review published by Mouafo et al, 2017 brought out the contradictory results obtained in 
Sub Saharan Africa regarding the implications of host genes in HIV/AIDS transmission. 
These polymorphisms have not yet been studied in the context of MTCT in a Cameroonian population. A 
study done by Nkenfou et al in 2013 described just the allelic frequencies of some of these genes. It is possible that the 
genetic risk factors shown to be involved in MTCT in other populations do not have the same impact in our study 
population, as the results obtained by different groups of investigators are contradictory. We hypothesized that, the 
presence of genetic variants modulating the expression and/or function of HIV-1 co-receptors or their chemokine 
ligands could affect MTCT in Cameroon. 
 
Materials and Methods 
Study Subjects 
 
              HIV infected mothers with babies less than 1 year were enrolled in the study. As a control group, a set of HIV 
non-infected mothers with babies less than one year old were also recruited, all from Yaounde city in Cameroon. 
Yaounde being the Capital of Cameroon, receives patients from almost all the geographic and ethnic groups of the 
country for their care and management. Every mother with her baby who accepted to participate and signed the consent 
form was included in the study. The mother-baby pair who has incomplete clinical data or has insufficient biological 
samples was excluded from the study. 
            Blood was collected from these mothers and babies for laboratory analyses.  
Maternal HIV status was established by Determine HIV 1/2 (Alere, 357 Matsuhidai, Matsuda-shi, Chiba, 270–2214 
Japan) and confirmed using the ONE STEP Anti-HIV1/2 TEST (STANDARD DIAGNOSTIC, INC 156-68 Hadal-
dong, Korea). Babies’ HIV status was determined by real time PCR using the Roche Amplicor HIV-1 DNA assay, 
version 1.5 (Roche Molecular Systems Inc, Branchburg, NJ). 
    Mothers and babies were grouped mainly according to the status of the mothers/ babies. We therefore had 3 
group of subjects in our study population: 
•Group 1: Mothers who did not transmit HIV to their babies (NT), hence their babies were exposed non-infected 
(EN). 
•Group 2: Mothers who have transmitted HIV to their babies (T), hence their babies were exposed infected (EI). 
•Control group: mothers who were not infected by HIV, thus non-exposed, non-infected babies. 
•In the HIV infected mothers there were some that were on treatment or prophylaxis and the babies also. 
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CD4+T Cell Counts and Plasma Viral Loads 
 
           CD4+ T cell counts of peripheral blood were determined using a FACS Calibur flow cytometer (Becton 
Dickinson Immuno-cytometry System (BDIS), San Jose, CA, USA). Plasma HIV-1 RNA loads were determined using 
the 200 µl protocol of Abbott real-time HIV-1 assay (Abbott Molecular Diagnostics, Wiesbaden, Germany) with a 
detection limit of 150 copies/ml (2.18 log) according to the manufacturer’s instructions. 
The HIV status of the babies was determined using the Amplicor HIV-1 Monitor kit version 1.5 (Roche Diagnostics, 
Alameda, CA) according to the manufacturer’s instructions. 
 
Genomic DNA Extraction and Genotyping 
 
Genomic DNA was extracted from buffy coat using the QIAamp DNA Mini Kit (QiagenGmbH, D-40724 
Hilden). The genotyping of CCR5-Δ32, CCR5 promoter 59029 A/G, CCR2-64I, SDF1-3’A was performed by PCR 
followed by RFLP using the protocol described previously by Magierowska et al. (1999), Kristiansen et al. (2001), 
Nkenfou et al., (2013). The genotyping of TRIM5α 136Q was done following the protocol described by van Manen et 
al. (2008). 
 
Ethical Considerations 
 
               The study was reviewed and approved by the national ethic committee under the Number 
N°2013/11/375/L/CNERH/SP and the division of operational research of the Ministry of Public Health of Cameroon 
under the number D30-63/L/MINSANTE/SG/DROS/CRC/CEA2/DTLC. The national and international regulations 
guiding the use of human subjects in biomedical research were followed during the study. Written informed consent 
was obtained from the mothers as well as proxi consent for their babies. 
 
Statistical Methods 
 
The allelic frequencies were calculated as (h + 2H)/2N, where H is the number of samples with a homozygous 
mutation genotype, h is the number with a heterozygous mutation genotype and N the total number of samples. The 
difference in the allele frequencies in between the different groups was further assessed using exact p-values from chi-
square test. Logistic regression was used to evaluate the association of genotypes with risk of HIV transmission and 
acquisition by the baby, with wild type as the references. Heterozygous and homozygous mutant genotypes compared 
to the homozygous wild type referent genotypes were examined. All analyses were adjusted for Randomized 
intervention study, Mother’s CD4 count and log HIV-1 RNA when assessing the implication of these polymorphisms in 
the MTCT, using the Epi info version 7.1.3.3 software. 
 
Results 
Study Population 
 
A total of 262 mothers (212 HIV infected and 50 HIV non-infected) with their 270 babies (42 HIV exposed 
infected, 178 HIV exposed non-infected and 50 HIV non-exposed, non-infected) were recruited. Of the 212 HIV 
infected mothers, 72.6 % (154/212) were under treatment, among which 12.3% (19/154) transmit HIV and 87.6% 
(135/154) did not transmit. The rest of 58 mothers who were not on treatment, 39.6% (23/58) transmit and 60.4% 
(35/58) did not.  Eight mothers gave birth to twins. From the 270 children, 50.7% (137/270) were girls and 49.3% 
(133/270) were boys. From the 42 HIV exposed infected infants, 45.2% (19/42) have received prophylaxis and 54.8% 
(23/42) did not. From the 178 exposed non-infected, 78.7% (140/178) have received prophylaxis and 21.3% (38/178) 
did not. 92.9% (158/170) of the non-transmitting mothers and 90.5% (38/42) of the transmitting mothers delivered by 
normal route. The three main ways of feeding were found in the study population. From the non-transmitting mothers 
37.7% (64/170) practice breast feeding, 53.5% (91/170) artificial and 8.8% (15/170) mixed feeding. In the transmitting 
mothers 40.5% (17/42) breast fed their babies, 33.3% (14/42) gave them bottle feeding (artificial) and 26.2% (11/42) 
practice mixed feeding. This population description is presented in Table 1. 
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Table 1: Demographic and clinical characteristics of the mothers and babies in the study population 
  group Age (Years for mother 
and weeks for babies) 
CD4 
(cells/mml) 
Viral laod (Log10 
RNA copies/ml) 
Feeding mode Delivery mode 
Mothers T (n=42) TWP 
(n=19) 
26.8±6.3 398(62-880) 2.94 (1.65-5.08) Maternal 
(40.5%) 
Artificial(33.3%) 
Mixed(26.2%) 
Caesarean (9.5) 
Normal 
(90.5%) 
 TWDP 
(n=23) 
28.4±5.5 338(44-999) 4.95 (2.52-5.79) 
NT 
(n=170) 
NTWP 
(n=135) 
29.6±5.5 475(135-
1159) 
3.71 (ND-5.56) Maternal 
(37.7%) 
Artificial(53.5% 
Mixed (8.8%) 
Caesarean 
(7.1%) 
Normal 
(92.9%) 
 
NTWDP 
(n=35) 
26.9±4.4 447.5 (250-
791) 
4.59 (ND-6.43) 
 HIV neg 
(n=50) 
25.7±5.4 843(513-
1390) 
NA Maternal (70%) 
Artificial (10% 
Mixed (20%) 
Caesarean(4% 
Normal (96%) 
 
Babies EI 
(n=42) 
EIWP 
(n=19) 
 
20.1± 11.5 2198 (621-
3050) 
5.4 (3-7) NA NA 
EIWDP 
(n=23) 
 
24.8±13.1 1040 (810-
2257) 
5.1 (2.74-8.1) NA NA 
EN 
(n=178) 
 
ENWP 
(n=140) 
 
12.7±10.4 2083 (442-
3759) 
NA NA NA 
ENWDP 
(n= 38) 
 
12.1±8.7 2234 (1732-
2897) 
NA NA NA 
 HIV neg 
(n=50) 
5.7±3.8 
 
2043 (1005-
3374) 
NA   
Continuous variables are presented as (Mean ±SD) and [ median (range)]. NA stand for not applicalble. TWP: 
transmitter with prevention protocole, TWDP: transmitter without prevention protocol, NTWP: non-transmitter with 
prevention protocol, NTWDP: non-transmitter without prevention protocol. EIWP : exposedinfectedwith prevention 
protocole, EIWDP : exposedinfectedwithout prevention protocol, ENWP : exposed non-infectedwith prevention 
protocole, ENWDP : exposed non-infectedwithout prevention protocol. HIV neg: Humanimmunodeficiency virus 
negative.  
 
          The CCR5- Δ32 mutation was completely absent from our study population.  
The allelic frequencies were 14.7%, 41.9%, 9.5% and 14.7% for CCR2-64I, CCR5-59029-A/G, TRIM5α-136Q, SDF1-
3’A respectively in the mothers and 18.8%, 35.9%, 11.3% and 20.5% in the babies (Table 2). 
 
Table 2: Allelic frequencies of the five ARG variants in the mother and baby study population 
 
 
 
Gene 
 
 
 
Allele 
 
 
Mothers 
 
babies 
Quantity (n) Number of 
subject (N) 
 
Allelic 
frequency (%) 
Quantity (n) Number of 
subject (N) 
 
Allelic 
frequency 
(%) 
CCR5-Δ32 WT 524 262 100 540 270 100 
- Δ32 0 0 0 0 0 0 
CCR2-64I G 447 258 85.3 439 266 81.2 
A 77 73 14.7 101 97 18.8 
CCR5-59029-
A/G 
A 304 223 58.1 345 238 64.1 
G 220 181 41.9 195 163 35.9 
TRIM5α-136Q G 474 262 90.5 479 269 88.7 
A 50 50 9.5 61 60 11.3 
SDF1-3’A G 447 262 85.3 429 269 79.5 
A 77 77 14.7 111 110 20.5 
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Association of chemokine receptors/ligands polymorphisms with the risk of HIV-1 transmission from mother-to-
child 
 
There was no significant difference in the frequencies of the AIDS related genes studied between the HIV 
infected and non-infected mothers, except for SDF1-3’A (p=0.025) as shown in Table 3.  
 
Table 3: Frequencies of polymorphisms among HIV-infected and non-infected mothers 
Gene Genotype HIV-infected mothers 
N (%) 
HIV non-infected mothers 
N (%) 
P value* 
CCR5-Δ32 WT 212 (100) 50 (100) NA 
Δ32 0 (0) 0 (0) 
CCR2-64I GG 154 (72.6) 34 (68) / 
GA 53 (25) 16 (32) 0.37 
AA 5 (2.4) 0 (0) 0.5 
CCR5-59029-A/G AA 63 (29.7) 18 (36) / 
AG 115 (54.2) 27 (54) 0.47 
GG 34 (16.1) 5 (10) 0.37 
TRIM5α- 136Q GG 169 (79.7) 43 (86) / 
GA 43 (20.3) 7 (14) 0.42 
AA 0 (0) 0 (0) 1 
SDF1-3’A GG 144 (67.9) 41 (82) / 
GA 68 (32.1) 9 (8) 0.04 
AA 0 (0) 0 (0) 1 
There was a significant difference in the frequency of SDF1-3’A (p=0.005) between the sub-populations of 
transmitter and non-transmitter mothers. Mothers, heterozygote for SDF1-3’A, were more frequent in the population of 
the non-transmitter than in the transmitters (36.5% and 14.3%). These data are presented in Table 4. The association of 
these different polymorphisms with the risk of HIV-1 transmission by logistic regression was analyzed: none of the 
polymorphisms were associated with the risk of transmission except for the SDF1-3’A (Table 5). We found that SDF1-
3’A [Odd ratio (OR) = 1.69; 95% confidence interval (CI): 0.1158 to 0.7277); P = 0.008) was associated with the 
protection against the transmission. 
 
Table 4: polymorphism in the different sub-group of mothers (Transmitter versus non-transmitter) 
Gene Genotype Transmitters 
N (%) 
Non-transmitters  
N (%) 
 
P value* 
CCR5-Δ32 WT 42 (100) 170 (100) NA 
Δ32 0 (0) 0 (0) 
CCR2-64I GG 29 (69.1) 126 (74.1) / 
GA 13 (30.9) 40 (23.5) 0.5 
AA 0 (0) 4 (2.4) 0.5 
CCR5-59029-A/G AA 14 (33.3) 49 (28.8) / 
AG 24 (57.1) 91 (53.5) 0.7 
GG 4 (9.6) 30 (17.6) 0.2 
TRIM5α- 136Q GG 34 (80.1) 135 (79.4) / 
GA 8 (19.1) 35 (20.6) 1 
AA 0 (0) 0 (0) 1 
SDF1-3’A GG 36 (85.7) 108 (63.5) / 
GA 6 (14.3) 62 (36.5) 0.005 
AA 0 (0) 0 (0) 1 
* P-value from chi-square test. Statistically significant results are marked in bold.  
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Table 5: Association of chemokine receptor and chemokine ligand polymorphism in the mother- baby pairs with 
MTCT of HIV-1 
Gene Genotype 
in 
mothers 
Percent 
transmission 
OR (95% 
CI)a 
 
P* Genotype 
in babies 
Percent of 
acquisition 
OR (95% 
CI) 
P* 
CCR2-64I GG 16.8 (29/155) 1.4318 
(0.6917-
2.9639) 0.3336 
GG 20.4 (29/142) 0.9313 
(0.4637 - 
1.8704) 
0.8415 
GA or 
AA 
22.8 (13/57) GA or 
AA 
17.7 (14/79) 
CCR5-
59029-
A/G 
AA 22.2 (14/63) 0.8099 
(0.3933 to 
1.6678 0.5673 
AA 14.9 (10/67) 1.5545 
(0.7167 - 
3.3720 0.2641 
AG or 
GG 
18.8 (28/149) AG or 
GG 
21.4 (33/154) 
TRIM5-
136Q 
GG 20.1 (34/169) 
0.9076 
(0.3859 to 
2.13) 
0.8241 GG 19.2 (33/171) 1.0455 
(0.4744 - 
2.3039) 
0.9122 
GA or 
AA 
18.6 (8/43) GA or 
AA 
20 (10/50) 
SDF1-
3’A 
GG 24.2 (36/149) 0.2903 
(0.11 to 
0.72) 
0.0083 GG 17.9 (24/134) 1.6947 
(0.86 - 
3.31) 
0.1228 
GA or 
AA 
9.5 (6/63) GA or 
AA 
21.8 (19/87) 
aAdjusted for mother’ CD4 count and RNA viral load. * P-value from the Logistic regression analysis. Statistically 
significant results are marked in bold.  
 
Association of chemokine receptors/ligands polymorphisms with the risk of HIV-1 acquisition by the baby from 
mother 
 
Looking at the two groups of exposed children, there was no significant difference in the distribution of the 
different polymorphisms except for the CCR5-59029-A/G. The Homozygote mutants for the CCR5-59029-A/G were 
significantly higher in the exposed infected than in the non-infected children (23.8% Vs.11.3%, p=0.04), see Table 6.  
For TRIM5α-136Q, infected babies had the higher frequencies of the heterozygote mutant genotype compared 
to the non-infected babies, with p=0.08, as shown in Table 6.  For the two other genes, CCR2-64I and CCR5-59029-
A/G mutation, there was no difference in the distribution between exposed-infected and exposed-non infected children. 
The frequency of Homozygote mutant genotypes did not show any difference between the two groups of children, data 
presented in Table 6. The regression analysis shows that no polymorphism was associated with the risk of HIV 
acquisition (Table 5). 
 
Table 6: Polymorphism of the study genes in the children population  
Gene Genotype HIV exposed infected 
N (%) 
 
HIV exposed non –infected 
N (%) 
 
p-value* 
CCR5-Δ32 WT 42 (100) 178 (100) NA 
Δ32 0 (0) 0 (0)  
CCR2-64I GG 29  (69.1) 113 (63.5) / 
GA 11 (26.2) 63 (35.4) 0.3 
AA 2 (4.7) 2 (1.1) 0.1 
CCR5-59029-A/G AA 10 (23.8) 57 (32) / 
AG 22 (52.4) 101 (56.7) 0.7 
GG 10 (23.8) 20 (11.3) 0.04 
TRIM5α- 136Q GG 32 (76.2) 138 (77.5) / 
GA 10 (23.8) 39 (21.9) 0.8 
AA 0 (0) 1(0.6) 1 
SDF1-3’A GG 20 (47.6) 110 (6.8) / 
GA 22 (52.4) 67(37.6) 0.08 
AA 0 (0) 1 (0.6) 1 
* P-value from chi-square test. NA: Not applicable. Statistically significant results are marked in bold 
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Association of chemokine receptors, intake of antiretroviral and chemokine polymorphisms with the risk of 
HIV-1 transmission from mother to child 
 
          In the multivariate regression analysis model the implication of both the ARV intake and the genotype mutation 
did not show any significant result concerning MTCT or the acquisition of HIV by the babies. Even though we found 
as already known that the intake of ARV reduced both the transmission and the level of acquisition (OR = 0.2065; 95% 
CI: 0.1011 to 0.4219; P< 0.001 and OR = 0.2149; 95% CI: 0.1066 to 0.4330; P<0.001 respectively). This intake of 
ARV do not have an effect on the protective role of the SDF1-3’A mutation in reducing the MTCT which remains the 
same.  
 
Discussion 
 
The aim of this study was to determine the distribution of CCR5-Δ32, CCR5-59029A/G, CCR2-64I, SDF1-3’A 
and TRIM5α-136Q polymorphisms in a Cameroonian cohort of mother-baby and also to look at their association with 
the MTCT and acquisition of HIV-1. To the best of our knowledge, no report has been published on the potential 
effects of these polymorphisms in a mother-baby Cameroonian population where some mothers have not transmitted 
HIV to their babies without any prevention.  
We have found that, CCR5-59029 G and SDF-1 3'801 were more frequent in the non-transmitter mothers than 
the transmitter mothers. SDF1-3’A was associated with the protection of the transmission. The CCR5-59029 G 
homozygote mutant was found to favor the acquisition of HIV by the babies from mothers. 
Compared to other studies, the allelic frequencies of the different mutant alleles were consistent with previous studies 
from African populations. In fact the homozygote CCR5 Δ32 mutation conferring resistance to R5-HIV-1 infection is 
rare or completely absent in African populations (Su et al., 2000; Sabeti et al., 2005, Torimiro et al., 2007; Nkenfou et 
al., 2013). The enrichment of the CCR5-Δ32 allele in European populations suggests that, this polymorphism most 
likely originated in Europe and then spread globally under natural positive selection, this can explain its absence in 
African population. 
For CCR2 64I, the allelic frequency in mothers and babies of 14.7 and 18.8% is similar to those obtained in 
other African populations (Su et al., 2000; Nkenfou et al., 2013), but higher than that of European and Asian 
populations (Su et al, 2000; Khabour et al., 2013). Although the frequency of CCR2 64I GA genotype was higher 
(35.4% versus 26.2%) in HIV exposed non-infected babies than in exposed infected, the difference was not significant. 
This may suggest its non-implication in the protection against acquisition of HIV by the babies from mothers. This 
result is not in agreement with previous reports (Mangano et al., 2000; Mabuka et al., 2009), where this genotype was 
involved in the protection against MTCT, as well as to those of Brouwer et al. (2005) and Singh et al. (2008) in 
Kenyan, South African, Ugandan and Malawian population (Singh et al., 2008), where this mutation has no impact in 
the MTCT.  
The CCR5-59029A/G mutation in the promoter region of the CCR5 gene has been widely studied in the 
pattern of HIV infection. The allelic frequency found in the studied population of 41.9%, and 35.9% (for the mother 
and baby respectively) were in the same ranges as those reported in the other studies of MTCT cohorts  (Singh et al., 
2008; Rathore et al., 2009), but less than what Katz et al. (2010) found in Kenyan population. The CCR5-59029 G 
homozygote mutant was more frequent in the non-transmitters than in the transmitters (17.6% Vs 9.6%), but with non 
significant p value (p=0.2). This may suggest a neutral role in the MTCT and this with adjusted mothers’ CD4 count 
and RNA viral load. The viral load and CD4 count are known to impact the transmission and the Carriage of CCR5 -
2459G mutation has been associated with reduced density of CCR5 on CD14+ monocytes and lower levels of R5 HIV 
propagation when compared to CCR5 -2459A (Kawamura et al., 2003; Salkowitz et al., 2003). A contradicting 
observation was found by Singh et al in 2008 and another study from Katz et al. (2010) did not find any association 
between CCR5-59029 G and the MTCT. In the babies population, the homozygote mutant of this mutation was 
significantly most frequent in the exposed infected babies than the exposed non-infected, thus favoring the acquisition 
of HIV (23.8% Vs 11.3%, p=0.04).   
The frequency of the alleleTRIM5α-136Q has not to the best of our knowledge, been reported in a study 
population regarding its implication in the MTCT. The observed 9.5% and 11.3% allelic frequencies (for the mother 
and baby respectively) are lower than the frequencies reported in American and Caucasian populations (Speelmon et 
al., 2006; van Manen et al., 2008). No association was found neither with the risk of transmission nor the acquisition of 
HIV. This has to be further investigated in a follow up cohort, as the reported implication of this mutation was mainly 
in disease progression and infectivity (Javanbakht et al., 2006; Speelmon et al., 2006). 
The SDF-1 3'A1 allelic frequency was higher among HIV non-infected than those reported among HIV-1 
infected women in Sub-Saharan Africa (John et al., 2000; Singh et al., 2008). Nkenfou et al. (2013) from a population 
of the same country found that all participants recruited were heterozygous for the SDF1-3'A allele. The genotypes of 
this allele were not in hardy Weinberg equilibrium. We think that it may be due to our sample size, as small population 
size can cause a random change in allele frequencies due to genetic drift. The effect of this allele has been suggested to 
protect from HIV-1 infection in women. There was a protective effect of this mutation in the MTCT based on its 
8 
 
frequency in the mothers who did not transmit, and this was further confirmed after the adjustment of mothers’ CD4 
count and RNA viral load. But none of this effect was found in babies’ population. Our results showed that the 
polymorphism in chemokine ligand may be involved in protecting against MTCT. Such protective effect has not been 
found by previous studies done on 19 cohorts from the United States, Europe, and Australia (Ioannidis et al., 2001).  
Although we did not have data on the duration of the infection in mothers, we may assume that most of the 
mothers were at the chronic stage of the infection. The effect of SDF-1 3'A1 variant occurs during the advanced stages 
of infection when the virus shifts from R5 to X4 strains. 
The discrepancy of our results with other studies may be explained by the difference in ethnicity and 
geography location and or the population size. 
Our study brought a contribution towards understanding host genetic variations with regard to MTCT among 
Africans, more specifically Cameroonians. However, there is a need to carry the study on a larger size population to 
understand the deviation from the hardy Weinberg equilibrium in respect to SDF-1 3'A1. 
 
Conclusions. From our study what came out was that SDF1-3’A was associated with the reduction of MTCT. The 
CCR5-59029-A/G favored the acquisition of HIV by babies. 
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